trending Market Intelligence /marketintelligence/en/news-insights/trending/0a-7scxhoglajlwwqfpewa2 content esgSubNav
In This List

Regenxbio prices $175.5M underwritten public offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Regenxbio prices $175.5M underwritten public offering

Regenxbio Inc. priced its underwritten public offering of common shares to raise $175.5 million in gross proceeds.

The gene therapy company will offer 2,700,000 shares at $65 per share and has granted the underwriters a 30-day option to purchase additional 405,000 shares to cover overallotments if any.

The offering is expected to close on or about Aug. 14, subject to customary closing conditions.

Rockville, Md.-based Regenxbio uses its NAV technology platform, an adeno-associated virus gene delivery platform, to engineer product candidates for the treatment of retinal, metabolic and neurodegenerative diseases.